Literature DB >> 23734682

Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer.

Ruiwu Liu1, Hiromi I Wettersten, See-Hyoung Park, Robert H Weiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23734682      PMCID： PMC4573579          DOI： 10.4155/fmc.13.56

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  19 in total

Review 1.  p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected].

Authors:  Jana Cmielová; M Rezáčová
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

Review 2.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

Review 3.  The role of apoptosis in cancer development and treatment response.

Authors:  J Martin Brown; Laura D Attardi
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

4.  Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Daniel R Greenwald; Erkki Ruoslahti
Journal:  Science       Date:  2010-04-08       Impact factor: 47.728

5.  Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.

Authors:  Hiromi Inoue; Sung Hee Hwang; Aaron T Wecksler; Bruce D Hammock; Robert H Weiss
Journal:  Cancer Biol Ther       Date:  2011-11-01       Impact factor: 4.742

6.  p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches.

Authors:  Robert H Weiss; Alexander D Borowsky; David Seligson; Pei-Yin Lin; Lisa Dillard-Telm; Arie S Belldegrun; Robert A Figlin; Allan D Pantuck
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

7.  High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers.

Authors:  See-Hyoung Park; Xiaobing Wang; Ruiwu Liu; Kit S Lam; Robert H Weiss
Journal:  Cancer Biol Ther       Date:  2008-12-26       Impact factor: 4.742

8.  Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands.

Authors:  R Klopfleisch; A D Gruber
Journal:  Res Vet Sci       Date:  2009-01-30       Impact factor: 2.534

9.  Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53.

Authors:  See-Hyoung Park; Jin-Young Park; Robert H Weiss
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

Review 10.  Examination of the expanding pathways for the regulation of p21 expression and activity.

Authors:  Yong-Sam Jung; Yingjuan Qian; Xinbin Chen
Journal:  Cell Signal       Date:  2010-01-25       Impact factor: 4.315
View more
  13 in total

Review 1.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

2.  Barrier Function of the Repaired Skin Is Disrupted Following Arrest of Dicer in Keratinocytes.

Authors:  Subhadip Ghatak; Yuk Cheung Chan; Savita Khanna; Jaideep Banerjee; Jessica Weist; Sashwati Roy; Chandan K Sen
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

3.  Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer.

Authors:  Wenmei Su; Shumei Feng; Xiuyuan Chen; Xia Yang; Rui Mao; Chunfang Guo; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Rishindra M Reddy; Mark B Orringer; Andrew C Chang; Zhixiong Yang; David G Beer; Guoan Chen
Journal:  Cancer Res       Date:  2018-04-18       Impact factor: 12.701

4.  In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma.

Authors:  Somnath Ghosal; Subrata Banerjee
Journal:  Med Oncol       Date:  2022-02-12       Impact factor: 3.064

Review 5.  The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy.

Authors:  Nina-Naomi Kreis; Frank Louwen; Juping Yuan
Journal:  Cancers (Basel)       Date:  2019-08-21       Impact factor: 6.639

Review 6.  The Role of the Cyclin Dependent Kinase Inhibitor p21cip1/waf1 in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics.

Authors:  Samar Al Bitar; Hala Gali-Muhtasib
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

7.  Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.

Authors:  Agnieszka Bojko; Joanna Czarnecka-Herok; Agata Charzynska; Michal Dabrowski; Ewa Sikora
Journal:  Cells       Date:  2019-11-23       Impact factor: 6.600

8.  RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence.

Authors:  Joseph L Regan; Dirk Schumacher; Stephanie Staudte; Andreas Steffen; Ralf Lesche; Joern Toedling; Thibaud Jourdan; Johannes Haybaeck; Dominik Mumberg; David Henderson; Balázs Győrffy; Christian R A Regenbrecht; Ulrich Keilholz; Reinhold Schäfer; Martin Lange
Journal:  iScience       Date:  2021-05-24

9.  Activation of the sympathetic nervous system suppresses mouse white adipose tissue hyperplasia through the β1 adrenergic receptor.

Authors:  Mary K Schneider; Bingzhong Xue; Hang Shi
Journal:  Physiol Rep       Date:  2018-04

10.  The Cell-Cycle Regulatory Protein p21CIP1/WAF1 Is Required for Cytolethal Distending Toxin (Cdt)-Induced Apoptosis.

Authors:  Bruce J Shenker; Lisa M Walker; Ali Zekavat; Robert H Weiss; Kathleen Boesze-Battaglia
Journal:  Pathogens       Date:  2020-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.